Show simple item record

dc.contributor.authorHo GN
dc.contributor.authorDouglas KMJ
dc.date.accessioned2024-04-25T09:06:29Z
dc.date.available2024-04-25T09:06:29Z
dc.date.issued03/04/2023
dc.identifier.citationHo GN, Douglas KMJ. Nintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort? Rheumatol Adv Pract. 2023 Apr 3;7(2):rkad037. doi: 10.1093/rap/rkad037. PMID: 37065010; PMCID: PMC10097451.
dc.identifier.doi10.1093/rap/rkad037
dc.identifier.pmid37065010
dc.identifier.urihttp://hdl.handle.net/20.500.14200/4343
dc.publisherOxford University Press
dc.subjectRheumatology
dc.titleNintedanib for progressive fibrosing interstitial lung disease: how many meet criteria in a UK district general hospital systemic sclerosis cohort?
dc.typeArticle
dc.source.journaltitleRheumatology Advances in Practice
dc.contributor.affiliationThe Dudley Group NHS Foundation Trust
oa.grant.openaccessNA


This item appears in the following Collection(s)

Show simple item record